Irras

Irras is a medical technology company focused on developing advanced devices for neurocritical care, specifically targeting intracranial pressure management to enhance patient outcomes in critical healthcare settings. Irras specializes in neurocritical care solutions, providing innovative products to manage intracranial pressure. Headquartered in Stockholm, Sweden, the company was founded by individuals with a commitment to improving patient care. Will Martin serves as the CEO.

In May 2016, Irras raised USD 11. 25 mn from Serendipity Ixora, marking a significant funding event in their growth trajectory. The total amount raised to date stands at USD 11. 25 mn.

Irras designs and manufactures medical devices aimed at neurocritical care, with the IRRAflow® system being a key product that combines automated irrigation and continuous intracranial pressure monitoring. This system is complemented by the Hummingbird product line, which features Hummingbird Solo and Hummingbird Quad systems for effective ICP management. These devices are utilized across various healthcare institutions in Europe and North America, focusing on enhancing patient outcomes in neurocritical cases. In the most recent year, 2023, Irras reported revenue of USD 4.

04 mn, with an EBITDA of USD -19. 53 mn. The company's revenue is primarily generated through direct sales of its medical devices to healthcare institutions specializing in critical care and neurology. Irras plans to leverage its recent funding from May 2016, amounting to USD 11.

25 mn, to support the development of new products and expand into new geographic markets. The company is focused on introducing enhanced versions of its IRRAflow® system and exploring opportunities in additional regions beyond Europe and North America. This strategic investment aims to strengthen their position in the neurocritical care market and further improve their product offerings.